No floor indeed. Reading the 1Q results they are clear that there will be little revs in '22 so I don't know how the SP has any chance of near-term upward movement. Partnering w/new CDMOs is great and all including running some studies, but biosynthetic manufacturing deals with defined pricing and supply are all that really matter.